J Cancer 2014; 5(2):133-142. doi:10.7150/jca.7773

Research Paper

Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment

Alexandre V. Ivachtchenko1,2,3✉, Oleg D. Mitkin2, Elizaveta V. Kudan2, Alexey A. Rjahovsky2, Anton A. Vorobiev2, Andrey S. Trifelenkov2, Natalia A. Shevkun2, Oxana V. Proskurina2, Dmitry V. Kravchenko2, Ruben N. Karapetian2

1. ChemDiv Inc., 6605 Nancy Ridge Drive, San Diego, CA 92121, USA
2. Chemical Diversity Research Institute, 141401 Khimki, Rabochaya str, 2a-1, Moscow Reg, Russia
3. Alla Chem LLC., 1835 E. Hallandale Beach Blvd, #442, Hallandale Beach, FL 33009, USA

Abstract

Recently new drugs targeting androgen-dependent axis have been approved for the treatment of castration-resistant prostate cancer (CRPC) - Zytiga and Xtandi (formerly MDV3100), several other candidates (for example, ARN-509) are in early phases of clinical trials. However despite significant improvement in overall survival with new treatments it is evident that resistance to these drugs develops. One of the approaches to overcome it is combination therapy and from this point of view some potential for drug-drug interactions can limit the application of the drug.

We describe here the preclinical development of ONC1-13B, antagonist of androgen receptor, with similar to MDV3100 and ARN-509 mechanism of action. It efficiently inhibits DHT-stimulated PSA expression and proliferation of prostate cancer cells, prevents binding of androgens to the AR ligand-binding domain, androgen-stimulated AR nuclear translocation and coactivator complex formation. In the LnCaP-Z2 xenograft model of prostate cancer ONC1-13B inhibits tumor growth and suppresses PSA expression. The in vivo activity of ONC1-13B is comparable to that of MDV3100 at similar doses, and even higher, calculated per unit of concentration in plasma. Distribution of ONC1-13B to the brain is less than that shown for MDV3100 and ARN-509, decreasing the risk of GABA-related seizure development. Additionally ONC1-13B induces significantly lower in vitro CYP3A activity than for example MDV3100 (known strong CYP3A inducer) or ARN-509 and could be well suited for co-therapy with drugs that are known CYP3A substrates. Thus ONC1-13B is a new promising antiandrogen demonstrating high efficacy in a preclinical model of prostate cancer, with lower potential for seizures and drug-drug interaction.

Keywords: ONC1-13B, Antiandrogen, Prostate Cancer

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Ivachtchenko AV, Mitkin OD, Kudan EV, Rjahovsky AA, Vorobiev AA, Trifelenkov AS, Shevkun NA, Proskurina OV, Kravchenko DV, Karapetian RN. Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer 2014; 5(2):133-142. doi:10.7150/jca.7773. Available from http://www.jcancer.org/v05p0133.htm